These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 35977199)
1. Association of Medicaid Managed Care Drug Carve Outs With Hepatitis C Virus Prescription Use. Auty SG; Shafer PR; Dusetzina SB; Griffith KN JAMA Health Forum; 2021 Aug; 2(8):e212285. PubMed ID: 35977199 [TBL] [Abstract][Full Text] [Related]
2. Medicaid Subscription-Based Payment Models and Implications for Access to Hepatitis C Medications. Auty SG; Shafer PR; Griffith KN JAMA Health Forum; 2021 Aug; 2(8):e212291. PubMed ID: 35977192 [TBL] [Abstract][Full Text] [Related]
3. Substance use disorder treatment carve outs in Medicaid managed care. Silverman AF; Westlake MA; Hinds OM; Harris SJ; Abraham AJ; Grogan CM; Andrews CM J Subst Use Addict Treat; 2024 Jun; 161():209357. PubMed ID: 38554998 [TBL] [Abstract][Full Text] [Related]
4. Association Between Medicaid Managed Care Coverage of Substance Use Services and Treatment Utilization. Auty SG; Cole MB; Wallace J JAMA Health Forum; 2022 Aug; 3(8):e222812. PubMed ID: 36218990 [TBL] [Abstract][Full Text] [Related]
5. Impact of Removing Medicaid Fee-for-Service Hepatitis C Virus (HCV) Treatment Restrictions on HCV Provider Experience with Medicaid Managed Care Organizations in New York City. Behrends CN; Gutkind S; Deming R; Fluegge KR; Bresnahan MP; Schackman BR J Urban Health; 2021 Aug; 98(4):563-569. PubMed ID: 32016914 [TBL] [Abstract][Full Text] [Related]
6. Effect of relaxing hepatitis C treatment restrictions on direct-acting antiviral use in a Medicaid program: an interrupted time series analysis. Herink MC; Geddes J; Vo K; Zaman A; Hartung DM J Manag Care Spec Pharm; 2021 Jul; 27(7):856-864. PubMed ID: 34185560 [No Abstract] [Full Text] [Related]
7. Coverage and Prior Authorization Policies for Medications for Opioid Use Disorder in Medicaid Managed Care. Abraham AJ; Andrews CM; Harris SJ; Westlake MM; Grogan CM JAMA Health Forum; 2022 Nov; 3(11):e224001. PubMed ID: 36331441 [TBL] [Abstract][Full Text] [Related]
8. Changes in Use of Hepatitis C Direct-Acting Antivirals After Access Restrictions Were Eased by State Medicaid Programs. Davey S; Costello K; Russo M; Davies S; Lalani HS; Kesselheim AS; Rome BN JAMA Health Forum; 2024 Apr; 5(4):e240302. PubMed ID: 38578628 [TBL] [Abstract][Full Text] [Related]
9. Assessing the burden of illness of chronic hepatitis C and impact of direct-acting antiviral use on healthcare costs in Medicaid. Roebuck MC; Liberman JN Am J Manag Care; 2019 Jun; 25(8 Suppl):S131-S139. PubMed ID: 31211526 [TBL] [Abstract][Full Text] [Related]
10. Differences Between Managed Care and Fee-for-Service Medicaid in the Use of Generics for High-Rebate Drugs: The Cases of Insulin Glargine and Glatiramer. Hernandez I; Gellad WF J Manag Care Spec Pharm; 2020 Feb; 26(2):154-159. PubMed ID: 32011961 [TBL] [Abstract][Full Text] [Related]
11. Access, Utilization, and Quality of Behavioral Health Integration in Medicaid Managed Care. McConnell KJ; Edelstein S; Hall J; Levy A; Danna M; Cohen DJ; Unützer J; Zhu JM; Lindner S JAMA Health Forum; 2023 Dec; 4(12):e234593. PubMed ID: 38153809 [TBL] [Abstract][Full Text] [Related]
12. Hepatitis C Direct-Acting Antiviral Treatment Selection, Treatment Failure, and Use of Drug-Drug Interactions in a State Medicaid Program. Keast SL; Holderread B; Cothran T; Skrepnek GH J Manag Care Spec Pharm; 2019 Nov; 25(11):1261-1267. PubMed ID: 31663456 [TBL] [Abstract][Full Text] [Related]
13. Hepatitis C Treatment Initiation Among US Medicaid Enrollees. Kapadia SN; Zhang H; Gonzalez CJ; Sen B; Franco R; Hutchings K; Wethington E; Talal A; Lloyd A; Dharia A; Wells M; Bao Y; Shapiro MF JAMA Netw Open; 2023 Aug; 6(8):e2327326. PubMed ID: 37540513 [TBL] [Abstract][Full Text] [Related]
14. Prescription Drug Utilization and Reimbursement Increased Following State Medicaid Expansion in 2014. Mahendraratnam N; Dusetzina SB; Farley JF J Manag Care Spec Pharm; 2017 Mar; 23(3):355-363. PubMed ID: 28230452 [TBL] [Abstract][Full Text] [Related]
15. Association of Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees. Wen H; Hockenberry JM; Pollack HA JAMA Netw Open; 2018 Sep; 1(5):e182943. PubMed ID: 30646185 [TBL] [Abstract][Full Text] [Related]
16. Medicaid Expansion and Restriction Policies for Hepatitis C Treatment. Furukawa NW; Ingber SZ; Symum H; Rapposelli KK; Teshale EH; Thompson WW; Zhu W; Roberts HW; Gupta N JAMA Netw Open; 2024 Jul; 7(7):e2422406. PubMed ID: 39012632 [TBL] [Abstract][Full Text] [Related]
17. Association Between Medicaid Prescription Drug Limits and Access to Medications and Health Care Use Among Young Adults With Disabilities. Geiger CK; Cohen JL; Sommers BD JAMA Health Forum; 2021 Jun; 2(6):e211048. PubMed ID: 35977173 [TBL] [Abstract][Full Text] [Related]
18. Use of behavioral health care in Medicaid managed care carve-out versus carve-in arrangements. Charlesworth CJ; Zhu JM; Horvitz-Lennon M; McConnell KJ Health Serv Res; 2021 Oct; 56(5):805-816. PubMed ID: 34312839 [TBL] [Abstract][Full Text] [Related]
19. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. McAdam-Marx C; McGarry LJ; Hane CA; Biskupiak J; Deniz B; Brixner DI J Manag Care Pharm; 2011 Sep; 17(7):531-46. PubMed ID: 21870894 [TBL] [Abstract][Full Text] [Related]
20. Removal of Medicaid Prior Authorization Requirements and Buprenorphine Treatment for Opioid Use Disorder. Christine PJ; Larochelle MR; Lin LA; McBride J; Tipirneni R JAMA Health Forum; 2023 Oct; 4(10):e233549. PubMed ID: 37862034 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]